European Association of Dermato-Oncology 16th European Post-Chicago Melanoma Skin Cancer Meeting 2026

16th European Post-Chicago Melanoma / Skin Cancer Meeting 2026 (EPCM) European Post-Chicago Melanoma / Skin Cancer Meeting (EPCM) 2026 – Hamburg, Germany Access the complete 16th European Post-Chicago Melanoma / Skin Cancer Meeting (EPCM) 2026, one of Europe’s leading educational conferences dedicated to melanoma, non-melanoma skin cancers, immunotherapy, precision oncology, and dermatologic oncology. Organized under the auspices of the Melanoma World Society (MWS) and the European Association of Dermato Oncology (EADO), this internationally recognized meeting brings together world-renowned experts to discuss the latest advances presented at ASCO 2026, cutting-edge clinical trials, emerging systemic therapies, personalized cancer treatment strategies, and evidence-based management of melanoma and skin cancer patients. Whether you are a dermatologist, medical oncologist, surgical oncologist, radiation oncologist, dermatopathologist, or oncology trainee, this comprehensive educational package provides valuable clinical insights into modern melanoma care and multidisciplinary skin cancer management. Who Should Watch? This educational program is ideal for: Dermatologists Medical Oncologists Surgical Oncologists Radiation Oncologists Dermatopathologists Oncology Fellows Dermatology Residents General Surgeons Plastic Surgeons Cancer Researchers Healthcare Professionals involved in Skin Cancer Care What You Will Learn After completing this educational program, participants will be able to: Review the most important ASCO 2026 melanoma updates Understand advances in non-melanoma skin cancer management Improve early detection using dermoscopy Apply the newest EADO 2026 clinical guidelines Evaluate Gene Expression Profiling (GEP) in melanoma Understand modern immune checkpoint inhibitor (ICI) strategies Manage immunotherapy-related adverse events Treat vulnerable patient populations including elderly and immunocompromised patients Optimize treatment sequencing for melanoma Understand personalized oncology approaches Apply neoadjuvant and adjuvant melanoma therapies Review the latest advances in Merkel Cell Carcinoma Learn about Metastatic Uveal Melanoma Understand the role of ImmTACs, Tebentafusp and emerging bi-specific therapies Explore current evidence regarding the abscopal effect of radiotherapy Course Topics ASCO 2026 Highlights Melanoma Non-Melanoma Skin Cancer Dermoscopy Dermoscopy for detection of all skin cancers Early diagnosis strategies Lifestyle & Cancer Outcomes Exercise Nutrition Timing of Immune Checkpoint Inhibitor Administration Merkel Cell Carcinoma Adjuvant Trials Neoadjuvant Therapy Radiotherapy Advanced Disease Management Vulnerable Skin Cancer Patients Family Planning Elderly & Frail Patients Immunocompromised Patients Immune Checkpoint Inhibitor Toxicity Long-term Toxicities Delayed Immune Toxicities Rechallenge Strategies Immunosuppressive Therapy Gene Expression Profiling (GEP) Best GEP Tests Oncotype DX Comparison Clinical Implementation Future Guidelines EADO Guidelines 2026 Basal Cell Carcinoma (BCC) Cutaneous Squamous Cell Carcinoma (CSCC) Current Clinical Trials Future Treatment Strategies Novel Immunotherapies ImmTACs Tebentafusp Brenetafusp Metastatic Uveal Melanoma Cutaneous Melanoma Personalized Oncology Precision Medicine Biomarker Guided Therapy Future of Individualized Cancer Care Melanoma Treatment Neoadjuvant Therapy Perioperative Treatment Adjuvant Immunotherapy Targeted Therapy Immune Checkpoint Inhibitors BRAF Mutated Melanoma Radiotherapy Abscopal Effect Current Clinical Evidence Satellite Symposia Metastatic Uveal Melanoma Cutaneous Squamous Cell Carcinoma Early Stage Melanoma Individualized Therapy Redefining Melanoma Care Merkel Cell Carcinoma Immunotherapy Why This Course? This conference delivers one of the most comprehensive reviews of melanoma and skin cancer management in 2026, combining the latest ASCO highlights, EADO guideline updates, precision oncology, immunotherapy, targeted therapy, gene expression profiling, Merkel Cell Carcinoma, cutaneous squamous cell carcinoma, basal cell carcinoma, and uveal melanoma into a single educational resource. Healthcare professionals will gain practical knowledge that can immediately improve patient care while staying current with rapidly evolving advances in dermatologic oncology.